Is Serum Irisin Level a Biomarker in Diabetic Polyneuropathy?
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30-75
SponsorGÜLDEN ANATACA
About this trial
Diabetic polyneuropathy is a common complication of type 2 diabetes mellitus associated with sensory impairment and functional disability. Irisin is a myokine that has been implicated in glucose metabolism and neuroprotection. This prospective observational case-control study aims to evaluate serum irisin concentrations in patients with diabetic polyneuropathy compared with diabetic patients without neuropathy and healthy controls, and to investigate whether serum irisin may serve as a biomarker for diabetic polyneuropathy.
Eligibility criteria
Qualifiers
Age between 30 and 75 years
Diagnosis of Type 2 Diabetes Mellitus for at least 1 year (for diabetic groups)
Ability to understand and sign informed consent
Willingness to participate in the study
Disqualifiers
Neuropathy due to causes other than diabetes (e.g., vitamin B12 deficiency, chronic alcohol use, chemotherapy-induced neuropathy)
Chronic kidney disease (eGFR <60 mL/min/1.73 m²)
Active infection
Myopathies or other muscle diseases
Trial design
Treatments tested in this trial
- Not listed
Trial groups
81 Participants
are grouped into 3 trial groupsSponsors and collaborators
GÜLDEN ANATACA
Lead sponsor
Istanbul Saglik Bilimleri University
Sponsor institution
Source ClinicalTrials.gov